Ghaziabad Online

Preeclampsia Overview

Preeclampsia is a hypertensive disorder in pregnancy-related to 2% to 8% of pregnancy-related complications worldwide. It results in 9% to 26% of maternal deaths in low-income countries and 16% in high-income countries. Preeclampsia is defined as new-onset hypertension. The parameters for initial identification of preeclampsia are specifically defined as a systolic blood pressure of 140 mm Hg or more or diastolic blood pressure of 90 mm Hg or more on two occasions at least 4 hours apart; or shorter interval timing of systolic blood pressure of 160 mm Hg or more or diastolic blood pressure of 110 mm Hgor more, all of which must be identified after 20 weeks of gestation.

“Preeclampsia Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Preeclampsia Market. 

The Preeclampsia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Preeclampsia Pipeline Report–

• Companies across the globe are diligently working toward developing novel Preeclampsia treatment therapies with a considerable amount of success over the years. Preeclampsia Key players such as – Comanche Biopharma, MirZyme, Evergreen Therapeutics, Dilafor, and others, are developing therapies for the Preeclampsia treatment 

• Preeclampsia Emerging therapies such as – Preeclampsia Research Project, EG-101, Tafoxiparin, and others are expected to have a significant impact on the Preeclampsia market in the coming years. 
• In May 2021, Dilafor initiated a In An Exploratory, Open label, Randomized, ParallelGroup, Pilot Study to evaluate Safety, Tolerability and Efficacy of daily, subcutaneous tafoxiparin treatment from the time of diagnosis for up to 4 weeks, in pregnant women who are diagnosed with pre-eclampsia between the 26th and 32nd weeks of gestation.   

Preeclampsia Pipeline Therapeutics Assessment

• Preeclampsia Assessment by Product Type
• Preeclampsia By Stage and Product Type
• Preeclampsia Assessment by Route of Administration
• Preeclampsia By Stage and Route of Administration
• Preeclampsia Assessment by Molecule Type
• Preeclampsia by Stage and Molecule Type

DelveInsight’s Preeclampsia Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Preeclampsia Drugs Under Different Phases of Clinical Development Include: 

• Preeclampsia Research Project: Comanche Biopharma
• Preeclampsia Research Project: MirZyme
• EG-101: Evergreen Therapeutics
• Tafoxiparin: Dilafor

Preeclampsia Pipeline Analysis:

The Preeclampsia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Preeclampsia treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Preeclampsia Treatment.
• Preeclampsia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Preeclampsia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Preeclampsia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Preeclampsia product details are provided in the report. Download the Preeclampsia pipeline report to learn more about the emerging Preeclampsia therapies

Preeclampsia Pipeline Market Drivers

• The rise in incidence rate of Preeclampsia
• Growing demand for reducing the mortality rate of mother and newborn

Preeclampsia Pipeline Market Barriers

• No specific treatment options
• Complexity of the disease

Get a Free Sample PDF Report to know more about Preeclampsia Pipeline Assessment https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr

Scope of Preeclampsia Pipeline Drug Insight    

• Coverage: Global
• Key Preeclampsia Companies: Comanche Biopharma, MirZyme, Evergreen Therapeutics, Dilafor, and others
• Key Preeclampsia Therapies: Preeclampsia Research Project, EG-101, Tafoxiparin, and others
• Preeclampsia Therapeutic Assessment: Preeclampsia current marketed and Preeclampsia emerging therapies
• Preeclampsia Market Dynamics: Preeclampsia market drivers and Preeclampsia market barriers 

Request for Sample PDF Report for Preeclampsia Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Preeclampsia drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com